跳至主要内容
临床试验/NCT04049110
NCT04049110已完成3 期

SGLT-2 Inhibition Using Dapagliflozin During and After Physical Exercise - Effects on Glycemic Variability, Hormonal Regulators of Glucose Homeostasis and Ketone Body in Type 1 Diabetes - a Randomized, Placebo-controlled, Open-label, Cross-over Intervention Study

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2020年8月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
39
试验地点
1
主要终点
Mean Amplitude of Glucose Excursions (MAGE) after physical exercise

研究概览

简要总结

Inhibitors of sodium-dependent glucose-transporter 2 (SGLT-2 inhibitors, including dapagliflozin) inhibit glucose reabsorption in renal tubular cells, hereby increasing glycosuria in the hyperglycemic state. Its mechanisms of action are independent of insulin, which makes SGLT-2 inhibitors a potential adjunct to insulin in type 1 diabetes mellitus (T1DM).

However, a higher risk for diabetic ketoacidosis (DKA) was reported in patients with T1DM taking SGLT-2 inhibitors. DKA depends on an accumulation of ketone bodies in the blood stream, which equals an accumulation of acids that lead to acidosis. The underlying mechanisms of this observation are unknown. Ketone body production depends on the molar ratio of glucagon to insulin, with insulin suppressing but glucagon stimulating ketone body production. This translates into higher production during relative insulin deficiency, carbohydrate deficiency, and prolonged fasting, which occurs during sickness but also physical exercise. Physical exercise is a recommended cornerstone in the treatment of T1DM and current treatment guidelines recommend both, reductions of insulin doses and ingestion of additional carbohydrates to avoid hypoglycemic events. These adaptions might increase relative insulin deficiency, hyperglycemia and glycaemic variability, which might in turn promote ketone body production. The addition of SGLT-2 inhibitors further may promote ketogenesis even though there are reports of SGLT-2 inhibitors increase Glucagon-like-peptide-1 (GLP-1) in patients with T1DM. GLP-1 is a suppressor of glucagon secretion. In summary, knowledge about the effects of SGLT-2 inhibition on ketone body production is scarce, especially during exercise in patients with T1DM.

The study seeks to illustrate the effect of SGLT-2 inhibition on glycemic variability and ketone body production during and after recreational exercise in patients with T1DM. The results of study 2 will provide the basis for future studies investigating the underlying mechanisms of potentially modified ketone body production during and after exercise under SGLT-2 inhibition.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Diagnosis of T1DM
  • Duration of T1DM > 5 years
  • Male or female sex
  • Insulin therapy via multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
  • Body mass index (BMI) between 20 and 29 kg/m2
  • Adherence to sufficient contraceptive measures (double barrier method combining hormonal with mechanical barriers).
  • Ability to perform a 60 minutes exercise session at 50% VO2max.

排除标准

  • Diagnosis of renal and/or hepatic dysfunction
  • History of malignancy of any kind
  • Intake of drugs influencing glucose homeostasis during the last three months
  • Alcohol or drug abuse
  • Inadequate vein status on both forearms
  • Active smoker
  • Known pregnancy, positive plasma beta human choriogonadotropine test prior to study inclusion or intention to become pregnant during the study period.

研究组 & 干预措施

Dapagliflozin first, placebo second

Experimental

Dapagliflozin followed by placebo

干预措施: Forxiga 10mg (Drug)

Dapagliflozin first, placebo second

Experimental

Dapagliflozin followed by placebo

干预措施: Placebo (Drug)

Placebo first, Dapagliflozin second

Experimental

Placebo followed by dapagliflozin

干预措施: Forxiga 10mg (Drug)

Placebo first, Dapagliflozin second

Experimental

Placebo followed by dapagliflozin

干预措施: Placebo (Drug)

结局指标

主要结局

Mean Amplitude of Glucose Excursions (MAGE) after physical exercise

时间窗: From completion of physical exercise at day 7 of each intervention period to 72 hours after

MAGE will be calculated via sensor glucose measurements obtained over 72 hours after physical exercise

次要结局

  • Area under the curve for glucagon-like peptide I before, during and after physical exercise(From time-point 0 to 120 minutes before, during and after physical exercise session)
  • Area under the curve for glucagon before, during and after physical exercise(From time-point 0 to 120 minutes before, during and after physical exercise session)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Dapagliflozin in Physical Exercise in Type 1 Diabetes | 临床试验